PMC:7441788 / 143-1685
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 239-248 | Body_part | denotes | malarials | http://purl.org/sig/ont/fma/fma46831 |
T2 | 421-429 | Body_part | denotes | endosome | http://purl.org/sig/ont/fma/fma67180 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T3 | 0-24 | Disease | denotes | Coronavirus Disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 26-34 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 47-94 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T6 | 47-80 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
T7 | 96-104 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T8 | 187-195 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T9 | 335-343 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T10 | 600-608 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T11 | 713-721 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T12 | 884-892 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T13 | 1137-1145 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T14 | 1232-1240 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T15 | 1347-1355 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T16 | 1430-1438 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 467-475 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T2 | 513-521 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T3 | 576-577 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T4 | 610-611 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T5 | 833-834 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T6 | 1073-1074 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T5 | 207-212 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T6 | 250-261 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T7 | 263-265 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T8 | 271-289 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T9 | 345-347 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T10 | 670-672 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T11 | 797-799 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T12 | 835-844 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T13 | 1036-1038 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T14 | 1075-1084 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T15 | 1209-1211 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T16 | 1323-1325 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T17 | 1405-1416 | Chemical | denotes | application | http://purl.obolibrary.org/obo/CHEBI_33232 |
T18 | 1420-1422 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T1 | 219-232 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | investigation | http://purl.bioontology.org/ontology/MEDDRA/10062026 |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T3 | 250-261 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T4 | 263-265 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T5 | 271-289 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T6 | 345-347 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T7 | 670-672 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T8 | 797-799 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T9 | 835-844 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T10 | 1036-1038 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T11 | 1075-1084 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T12 | 1209-1211 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T13 | 1323-1325 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T14 | 1420-1422 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T2 | 0-24 | Species | denotes | Coronavirus Disease 2019 | NCBItxid:2697049 |
T3 | 26-34 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T4 | 47-94 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | NCBItxid:2697049 |
T5 | 96-106 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
T6 | 187-195 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T7 | 335-343 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T8 | 600-608 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T9 | 713-723 | Species | denotes | SARS-CoV-2 | NCBItxid:2697049 |
T10 | 884-892 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T11 | 1137-1145 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T12 | 1232-1240 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T13 | 1347-1355 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T14 | 1430-1438 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T7 | 0-132 | Sentence | denotes | Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide. |
T8 | 133-196 | Sentence | denotes | Antiviral therapy is the most important treatment for COVID-19. |
T9 | 197-344 | Sentence | denotes | Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19. |
T10 | 345-522 | Sentence | denotes | CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity. |
T11 | 523-609 | Sentence | denotes | These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. |
T12 | 610-759 | Sentence | denotes | A number of in vitro studies revealed inhibitory effects of CQ/HCQ on various coronaviruses, including SARS-CoV-2 although conflicting results exist. |
T13 | 760-985 | Sentence | denotes | Several clinical studies showed that CQ/HCQ alone or in combination with a macrolide may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay disease progression, with less serious adverse effects. |
T14 | 986-1146 | Sentence | denotes | However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. |
T15 | 1147-1250 | Sentence | denotes | Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. |
T16 | 1251-1542 | Sentence | denotes | Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
40 | 797-803 | Gene | denotes | CQ/HCQ | |
41 | 47-94 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
42 | 96-106 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
43 | 398-411 | Species | denotes | coronaviruses | Tax:11118 |
44 | 688-701 | Species | denotes | coronaviruses | Tax:11118 |
45 | 713-723 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
46 | 1123-1131 | Species | denotes | patients | Tax:9606 |
47 | 1241-1249 | Species | denotes | patients | Tax:9606 |
48 | 250-261 | Chemical | denotes | chloroquine | MESH:D002738 |
49 | 263-265 | Chemical | denotes | CQ | MESH:D002738 |
50 | 271-289 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
51 | 291-294 | Chemical | denotes | HCQ | MESH:D006886 |
52 | 670-672 | Chemical | denotes | CQ | MESH:D002738 |
53 | 673-676 | Chemical | denotes | HCQ | MESH:D006886 |
54 | 835-844 | Chemical | denotes | macrolide | MESH:D018942 |
55 | 1036-1042 | Chemical | denotes | CQ/HCQ | |
56 | 1075-1084 | Chemical | denotes | macrolide | MESH:D018942 |
57 | 1209-1211 | Chemical | denotes | CQ | MESH:D002738 |
58 | 1212-1215 | Chemical | denotes | HCQ | MESH:D006886 |
59 | 1323-1325 | Chemical | denotes | CQ | MESH:D002738 |
60 | 1326-1329 | Chemical | denotes | HCQ | MESH:D006886 |
61 | 1420-1422 | Chemical | denotes | CQ | MESH:D002738 |
62 | 1423-1426 | Chemical | denotes | HCQ | MESH:D006886 |
63 | 0-24 | Disease | denotes | Coronavirus Disease 2019 | MESH:C000657245 |
64 | 26-34 | Disease | denotes | COVID-19 | MESH:C000657245 |
65 | 187-195 | Disease | denotes | COVID-19 | MESH:C000657245 |
66 | 335-343 | Disease | denotes | COVID-19 | MESH:C000657245 |
67 | 600-608 | Disease | denotes | COVID-19 | MESH:C000657245 |
68 | 884-892 | Disease | denotes | COVID-19 | MESH:C000657245 |
69 | 924-937 | Disease | denotes | delay disease | MESH:D003141 |
70 | 1137-1145 | Disease | denotes | COVID-19 | MESH:C000657245 |
71 | 1232-1240 | Disease | denotes | COVID-19 | MESH:C000657245 |
72 | 1347-1355 | Disease | denotes | COVID-19 | MESH:C000657245 |
73 | 1430-1438 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 12-19 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | Disease |
T2 | 133-142 | http://purl.obolibrary.org/obo/IDO_0000559 | denotes | Antiviral |
T3 | 872-880 | http://purl.obolibrary.org/obo/OGMS_0000020 | denotes | symptoms |
T4 | 930-937 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | disease |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 239-248 | Body_part | denotes | malarials | http://purl.org/sig/ont/fma/fma46831 |
T2 | 421-429 | Body_part | denotes | endosome | http://purl.org/sig/ont/fma/fma67180 |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 430-443 | http://purl.obolibrary.org/obo/GO_0045851 | denotes | acidification |
T2 | 467-482 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T2 | 0-24 | Disease | denotes | Coronavirus Disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 26-34 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 47-94 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 96-106 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T6 | 187-195 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T7 | 335-343 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T8 | 600-608 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T9 | 713-723 | Disease | denotes | SARS-CoV-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T10 | 884-892 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T11 | 1137-1145 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T12 | 1232-1240 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T13 | 1347-1355 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T14 | 1430-1438 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sample-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 1174-1195 | Phenotype | denotes | prolonged QT interval | http://purl.obolibrary.org/obo/HP_0001657 |
LitCovid-sample-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 430-443 | http://purl.obolibrary.org/obo/GO_0045851 | denotes | acidification |
T2 | 467-482 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 430-443 | http://purl.obolibrary.org/obo/GO_0045851 | denotes | acidification |
T2 | 467-482 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
40 | 797-803 | Gene | denotes | CQ/HCQ | |
41 | 47-94 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
42 | 96-106 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
43 | 398-411 | Species | denotes | coronaviruses | Tax:11118 |
44 | 688-701 | Species | denotes | coronaviruses | Tax:11118 |
45 | 713-723 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
46 | 1123-1131 | Species | denotes | patients | Tax:9606 |
47 | 1241-1249 | Species | denotes | patients | Tax:9606 |
48 | 250-261 | Chemical | denotes | chloroquine | MESH:D002738 |
49 | 263-265 | Chemical | denotes | CQ | MESH:D002738 |
50 | 271-289 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
51 | 291-294 | Chemical | denotes | HCQ | MESH:D006886 |
52 | 670-672 | Chemical | denotes | CQ | MESH:D002738 |
53 | 673-676 | Chemical | denotes | HCQ | MESH:D006886 |
54 | 835-844 | Chemical | denotes | macrolide | MESH:D018942 |
55 | 1036-1042 | Chemical | denotes | CQ/HCQ | |
56 | 1075-1084 | Chemical | denotes | macrolide | MESH:D018942 |
57 | 1209-1211 | Chemical | denotes | CQ | MESH:D002738 |
58 | 1212-1215 | Chemical | denotes | HCQ | MESH:D006886 |
59 | 1323-1325 | Chemical | denotes | CQ | MESH:D002738 |
60 | 1326-1329 | Chemical | denotes | HCQ | MESH:D006886 |
61 | 1420-1422 | Chemical | denotes | CQ | MESH:D002738 |
62 | 1423-1426 | Chemical | denotes | HCQ | MESH:D006886 |
63 | 0-24 | Disease | denotes | Coronavirus Disease 2019 | MESH:C000657245 |
64 | 26-34 | Disease | denotes | COVID-19 | MESH:C000657245 |
65 | 187-195 | Disease | denotes | COVID-19 | MESH:C000657245 |
66 | 335-343 | Disease | denotes | COVID-19 | MESH:C000657245 |
67 | 600-608 | Disease | denotes | COVID-19 | MESH:C000657245 |
68 | 884-892 | Disease | denotes | COVID-19 | MESH:C000657245 |
69 | 924-937 | Disease | denotes | delay disease | MESH:D003141 |
70 | 1137-1145 | Disease | denotes | COVID-19 | MESH:C000657245 |
71 | 1232-1240 | Disease | denotes | COVID-19 | MESH:C000657245 |
72 | 1347-1355 | Disease | denotes | COVID-19 | MESH:C000657245 |
73 | 1430-1438 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T7 | 0-132 | Sentence | denotes | Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide. |
T8 | 133-196 | Sentence | denotes | Antiviral therapy is the most important treatment for COVID-19. |
T9 | 197-344 | Sentence | denotes | Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19. |
T10 | 345-522 | Sentence | denotes | CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity. |
T11 | 523-609 | Sentence | denotes | These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. |
T12 | 610-759 | Sentence | denotes | A number of in vitro studies revealed inhibitory effects of CQ/HCQ on various coronaviruses, including SARS-CoV-2 although conflicting results exist. |
T13 | 760-985 | Sentence | denotes | Several clinical studies showed that CQ/HCQ alone or in combination with a macrolide may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay disease progression, with less serious adverse effects. |
T14 | 986-1146 | Sentence | denotes | However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. |
T15 | 1147-1250 | Sentence | denotes | Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. |
T16 | 1251-1542 | Sentence | denotes | Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 1174-1195 | Phenotype | denotes | prolonged QT interval | http://purl.obolibrary.org/obo/HP_0001657 |